• AstraZeneca sells Atacand rights to Cheplapharm pharmatimes
    July 25, 2018
    AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
PharmaSources Customer Service